000 01585 a2200457 4500
005 20250513220156.0
264 0 _c20000907
008 200009s 0 0 eng d
022 _a1525-4135
024 7 _a10.1097/00126334-199912150-00006
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMurri, R
245 0 0 _aIntravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors.
_h[electronic resource]
260 _bJournal of acquired immune deficiency syndromes (1999)
_cDec 1999
300 _a461-6 p.
_bdigital
500 _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAnti-HIV Agents
_xtherapeutic use
650 0 4 _aCohort Studies
650 0 4 _aCross-Sectional Studies
650 0 4 _aDrug Prescriptions
650 0 4 _aFemale
650 0 4 _aHIV Infections
_xdrug therapy
650 0 4 _aHIV Protease Inhibitors
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aPhysician-Patient Relations
650 0 4 _aSubstance Abuse, Intravenous
700 1 _aFantoni, M
700 1 _aDel Borgo, C
700 1 _aIzzi, I
700 1 _aVisonĂ , R
700 1 _aSuter, F
700 1 _aBanfi, M C
700 1 _aBarchi, E
700 1 _aOrchi, N
700 1 _aBosco, O
700 1 _aWu, A W
773 0 _tJournal of acquired immune deficiency syndromes (1999)
_gvol. 22
_gno. 5
_gp. 461-6
856 4 0 _uhttps://doi.org/10.1097/00126334-199912150-00006
_zAvailable from publisher's website
999 _c10909156
_d10909156